Eagle Pharmaceuticals, Inc.
EGRX · OTC
3/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.02 | 0.44 | -3.63 |
| FCF Yield | 0.00% | 13.36% | 4.20% | 7.76% |
| EV / EBITDA | 0.00 | 5.04 | 704.51 | 18.75 |
| Quality | ||||
| ROIC | 0.00% | 15.51% | 2.55% | 7.77% |
| Gross Margin | 0.00% | 70.01% | 75.41% | 75.79% |
| Cash Conversion Ratio | -11.55 | 1.42 | -3.27 | 4.13 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.02% | -4.33% | -4.16% | -6.11% |
| Free Cash Flow Growth | -39.04% | 81.11% | -42.78% | -11.70% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.16 | -80.09 | -2.16 |
| Interest Coverage | 0.00 | 20.01 | 1.69 | 12.79 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 1.99 | 1.93 | 5.63 |
| Cash Conversion Cycle | 0.00 | 195.40 | 135.69 | 113.85 |